Sponsor content
188 result(s) found, displaying 1 to 10
- Designation or determinationNotice for lanadelumab (Takeda Pharmaceuticals Australia Pty Ltd)Orphan drug
- Jan-2023Prescription medicine evaluationADCETRIS Takeda Pharmaceuticals Australia Pty LtdActive ingredient: Brentuximab vedotin.
- ARTGGuanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack (395373)Australian Register of Therapeutic Goods (ARTG) information for Guanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack.
- ARTGGuanfacine 4 TAKEDA, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack (395374)Australian Register of Therapeutic Goods (ARTG) information for Guanfacine 4 TAKEDA, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack.
- ARTGGuanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack (395369)Australian Register of Therapeutic Goods (ARTG) information for Guanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack.
- ARTGGuanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack (395368)Australian Register of Therapeutic Goods (ARTG) information for Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack.
- Nov-2022Prescription medicine evaluationENTYVIO/KYNTELES Takeda Pharmaceuticals Australia Pty LtdActive ingredient: vedolizumab.
- Prescription medicine decision summaryLivtencityLivtencity (maribavir) is approved to treat cytomegalovirus (CMV).
- ARTGLIVTENCITY maribavir 200 mg film coated tablet bottle (380132)Australian Register of Therapeutic Goods (ARTG) information for LIVTENCITY maribavir 200 mg film coated tablet bottle.
- Prescription medicine registrationLIVTENCITY (Takeda Pharmaceuticals Australia Pty Ltd)Active ingredients: maribavir.